Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130026 · ClinicalTrials.gov registry record · NA
Caffeine in the Prevention of Post-operative Nausea and Vomiting
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 135
- Enrollment target
NCT00130026 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 135 participants.
The verdict
NCT00130026, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 135 participants
- Enrollment target
Study Summary
The objective of this study is to determine if caffeine 500 mg intravenously is efficacious when added to standard anti-emetic prophylaxis in the prevention of post-operative nausea and vomiting (PONV) in patients undergoing ambulatory surgery under general anesthesia.
Interventions
- DRUG Caffeine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130026
The ClinicalTrials.gov registry entry for NCT00130026 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Caffeine is the first listed.
NCT00130026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130026 about?
NCT00130026 is a clinical study titled "Caffeine in the Prevention of Post-operative Nausea and Vomiting". The objective of this study is to determine if caffeine 500 mg intravenously is efficacious when added to standard anti-emetic prophylaxis in the prevention of post-operative nausea and vomiting (PONV) in patients undergoing ambulatory surgery under general anesthesia.
What is the current status of trial NCT00130026?
This trial is currently completed. It is a NA study. The enrollment target is 135 participants. The study started on 2005-03. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00130026?
The interventions under investigation include: Caffeine (DRUG).
Who is sponsoring clinical trial NCT00130026?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.